Cadila Healthcare’s 70 per cent stake buy in South Africa-based Simayla Pharmaceuticals gives it a larger presence, well spread marketing network and a product basket that is skewed towards the generic medicines catering to the chronic segment. The stock closed 2 per cent down in a weak market.

Bookmark: